Hepatitis B Virus Clinical Trial
Official title:
A Prospective,Multi-center,Cohort Trial: the Efficacy and Safety of Tenofovir Alafenamide Fumarate Tablets (TAF) in Blocking Mother-to-child Transmission of Hepatitis B Virus(HBV)
This study is a single-group, multi-center and prospective clinical study designed to assess the efficacy and safety of TAF in blocking mother-to-child transmission of hepatitis B virus.Pregnant women whose HBsAg and HBeAg are positive are included in the study.Eligible hepatitis B pregnant women are given TAF antiviral therapy at 24-28 weeks of gestation to block mother-to-child transmission and followed up during pregnancy and after delivery.The study will be initiated with approval by the central ethics committee.Subjects will start screening after signing the informed consent form. Those who meet the criteria will start taking TAF (25mg, oral, 1/day) at 24-28 weeks of gestation until one month after delivery.At that time, chronic hepatitis B carrier will stop taking antiviral therapy, and patients with chronic hepatitis B decide whether to continue the therapy according to the patient's condition.The babies born are immunized according to the national standard immunization program,, that is, 100 IU of hepatitis B immunoglobulin (HBIG) and 10 μg/0.5 ml of hepatitis B vaccine are given within 12 hours after birth. And the same dose of hepatitis B vaccine is given at 1 month and 6 months of age.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03459521 -
Efficacy of HBVaxpro40© and Fendrix© in Patients With Chronic Liver Disease.
|
N/A | |
| Completed |
NCT02060162 -
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
|
||
| Completed |
NCT00912847 -
Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma
|
N/A | |
| Completed |
NCT04072211 -
Demonstration Project on Health Care Worker Protection Against Hepatitis B in Kalulushi District
|
Phase 4 | |
| Completed |
NCT01204762 -
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
|
Phase 2 | |
| Completed |
NCT00805675 -
Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB
|
Phase 3 | |
| Completed |
NCT02785835 -
Hepatocellular Carcinoma in HIV-infected Patients
|
||
| Completed |
NCT03083821 -
A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting
|
Phase 1 | |
| Recruiting |
NCT01083251 -
The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic Hepatitis B Virus (HBV) Infection
|
N/A | |
| Not yet recruiting |
NCT05752890 -
A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma
|
||
| Recruiting |
NCT04231565 -
Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.
|
N/A | |
| Terminated |
NCT00678587 -
Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
|
Phase 3 | |
| Completed |
NCT00739752 -
Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics
|
N/A | |
| Completed |
NCT03294798 -
Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04385524 -
Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection
|
N/A | |
| Enrolling by invitation |
NCT00663182 -
Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis
|
Phase 4 | |
| Completed |
NCT00769730 -
Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication
|
N/A | |
| Completed |
NCT01438424 -
Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials
|
Phase 2 | |
| Withdrawn |
NCT04046107 -
Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy
|
Phase 1/Phase 2 | |
| Completed |
NCT05406089 -
Effects of Antiviral Therapy on Patients With HBV-related HCC
|